ArticleBiochemical and biophysical research communications2011
Pilot analysis of the plasma metabolite profiles associated with emphysematous Chronic Obstructive Pulmonary Disease phenotype.
Article in Biochemical and biophysical research communications, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Persistence of circulating endothelial microparticles in COPD despite smoking cessation.Thorax · 2016Trial
- From metabolic alterations to chronic inflammation: mechanisms and immunoregulation of metabolic reprogramming in COPD.Frontiers in immunology · 2025Review
- Review
- Plasma metabolomics and quantitative interstitial abnormalities in ever-smokers.Respiratory research · 2023Article
- Detection of the Disorders of Glycerophospholipids and Amino Acids Metabolism in Lung Tissue From Male COPD Patients.Frontiers in molecular biosciences · 2022Article
- Imbalance Between Injury and Defense in the COPD Emphysematous Phenotype.Frontiers in medicine · 2021Review
- Plasma metabolomics and clinical predictors of survival differences in COPD patients.Respiratory research · 2019Article
- Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study.Scientific reports · 2019Article
- Role of medical and molecular imaging in COPD.Clinical and translational medicine · 2019Review
- Metabolomics Identifies Novel Blood Biomarkers of Pulmonary Function and COPD in the General Population.Metabolites · 2019Article
- Cigarette Smoke Reduces Fatty Acid Catabolism, Leading to Apoptosis in Lung Endothelial Cells: Implication for Pathogenesis of COPD.Frontiers in pharmacology · 2019Article
- Metabolic reprogramming in the pathogenesis of chronic lung diseases, including BPD, COPD, and pulmonary fibrosis.American journal of physiology. Lung cellular and molecular physiology · 2018Review
- Phenotyping of Chronic Obstructive Pulmonary Disease Based on the Integration of Metabolomes and Clinical Characteristics.International journal of molecular sciences · 2018Article
- Using omics approaches to understand pulmonary diseases.Respiratory research · 2017Review
- Metabolic Disorders in Chronic Lung Diseases.Frontiers in medicine · 2017Review
- Article
- Defining phenotypes in COPD: an aid to personalized healthcare.Molecular diagnosis & therapy · 2014Review
- Biomarkers in chronic obstructive pulmonary disease: confusing or useful?International journal of chronic obstructive pulmonary disease · 2014Review
- Fusion of theMetabolomics : Official journal of the Metabolomic SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The current pilot study examined the hypothesis that cigarette smokers who developed an emphysematous phenotype of Chronic Obstructive Pulmonary Disease (COPD) were associated with distinctive patterns in their corresponding metabolomics profile as compared to those who did not. Peripheral blood plasma samples were collected from 38 subjects with different phenotypes of COPD. They were categorized into three groups: healthy non-smokers (n=16), smokers without emphysema (n=8), and smokers with emphysema (n=14). Ultra High Performance Liquid Chromatography/quadrupole-Time-of-Flight Mass Spectrometry techniques were used to identify a large number of metabolite markers (3534). Unsupervised clustering analysis accurately separated the smokers with emphysema from others without emphysema and demonstrated potentials of this metabolomics data. Subsequently predictive models were created with a supervised learning set, and these predictive models were found to be highly accurate in identifying the subjects with the emphysematous phenotype of COPD with excellent sensitivity and specificity. Our methodology provides a preliminary model that differentiates an emphysematous COPD phenotype from other COPD phenotypes on the basis of the metabolomics profiles. These results also suggest that the metabolomics profiling could potentially guide the characterization of relevant metabolites that leads to an emphysematous COPD phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.